Drug Profile
Infliximab biosimilar - Nichiiko Pharmaceutical/Aprogen
Alternative Names: GS 071; NI-071Latest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator Aprogen; Nichiiko Pharmaceutical
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 20 Apr 2022 No development reported - Phase-III for Rheumatoid arthritis in Czech Republic (IV)
- 20 Apr 2022 No development reported - Phase-III for Rheumatoid arthritis in Poland (IV)
- 20 Apr 2022 No development reported - Phase-III for Rheumatoid arthritis in Spain (IV)